Thanks to the FDA's new AI-powered imaging tool, the safety profile of newly developed biosimilar therapeutic protiens may improve.

Andrew Brown, Head of Process Development Sciences at Lonza, talks about Lonza's approach to process development.

Are plant-derived peptides set to replace animal proteins as the go-to supplement for muscle conditioning?

We gain a glimpse into what the landscape of antisense oligonucleotides looks like today, from computational representations to protein purification.

New COVID variants are still a significant risk; but could an AI-generated universal COVID vaccine be the key to overcoming this?

AI/ML approaches are not some miracle ‘one size fits all' fix-all for delays and holdups in CGT manufacture, but the proper implementation of deep learning approaches and data interpretation may help speed up development.

Oxford Global's panel discussion brings together expert scientists in the field of immunology and biomarker development.

Scott Burger, Principal of Advanced Cell and Gene Therapy, discusses some of the recent trends in regulation and policy surrounding cell and gene therapy development.

An interview with Michael Thiele, Chief Scientific Officer, OncoOne Research & Development GmbH.

Researchers at the University of Washington have succeeded in using machine learning to synthesise artificial enzymes which are actually functional in cells.

As more developers bring their cell and gene therapy products to industry regulators, the need to drive cost and process efficiencies is on track to keep growing. Across the board, AI and machine learning approaches have the potential to streamline many aspects of development.

The investigational bispecific antibody has demonstrated favourable efficacy and safety in preclinical in vivo testing.